New possibilities of pharmacotherapy for chronic obstructive pulmonary disease
The use of bronchodilators (DB) remains up to the present day the leading therapeutic strategy for the treatment of chronic obstructive pulmonary disease (COPD), in which case administration of fixed-dose combinations of long-acting bronchodilators seem the most promising. At the same time, the issu...
Main Authors: | A. I. Sinopalnikov, A. G. Romanovskikh, Yu. G. Belotserkovskaya |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2018-10-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/2668 |
Similar Items
-
Fixed-dose combinations of bronchodilators in the treatment of patients with COPD: problem of choice
by: A. I. Sinopalnikov
Published: (2018-10-01) -
Experience of using a triple fixed combination in the treatment of patients with chronic obstructive pulmonary disease
by: Elena V. Bolotova, et al.
Published: (2022-03-01) -
Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan
by: Akira Umeda, et al.
Published: (2023-04-01) -
Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
by: Peter R. Bremner, et al.
Published: (2018-01-01) -
Increased treatment adherence in patients with chronic obstructive pulmonary disease when using a fixed triple combination
by: E. V. Bolotova, et al.
Published: (2021-10-01)